BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX® in the territory of South Korea.

BMG Pharma S.r.l will receive an undisclosed down payment from Samyang Biopharmaceutical Corporation who will exclusively market GelX® in South Korea.

GelX® will allow patients to receive the best care possible by using an innovative delivery technology to provide fast pain relief and eliminate swallowing issues and discomfort associated with mucositis related to chemotherapy, radiotherapy, and other pharmacologic therapies.

BMG 's team were the originators of some of the major Rx medical devices in cancer supportive care including Radiation Dermatitis and Xerostomia and we are sure we are providing the market with a new generation of innovative products for support of cancer patients and we are very pleased of the commitment from a major company like SAMYANG for GelX® said Marco Mastrodonato, President and CEO of BMG Pharma S.r.l.

We are very pleased to work with BMG Pharma S.r.l. to launch GelX® in the South Korean market, said Cheolho Kwak, President of Samyang Biopharmaceutical Corporation, because the delivery technology associated with GelX® is a significant breakthrough in ease of use and compliance associated with patients presenting with especially chemotherapy/radiotherapy-induced Oral Mucositis.

Source:

BMG Pharma S.r.l.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care